Konference: 2006 2. ročník Dny diagnostické, prediktivní a experimentální onkologie
Nádorová biologie/imunologie/genetika a buněčná terapie
Číslo abstraktu: 026p
Autoři: RNDr. Tatiana Matáková, Ph.D.; M. Sivoňová; RNDr. Jozef Hatok, Ph.D.; M. Franeková; L. Strelka; Prof. MUDr. Pavol Žúbor, DrSc.; Prof. MUDr. Dušan Dobrota, CSc.
The glutathione S-transferase (GST) genes are
involved in the metabolism of various carcinogens. Deletion
polymorphisms in the genes GSTM1 (Deletions in GSTM1 occur at a
frequency of about 15% in human populations. Individuals who are
deletion homozygous, i.e., GSTM1 null, exhibit and absence of
enzyme activity. A null allele at the GSTM1 locus is found in 40
%245 % of Caucasians. GSTM1 deficiency may be a risk factor for
cancer by providing increased sensitivity to chemical carcinogens.
The mechanism of carcinogenicity may be related to an increased
formation of DNA adducts in the presence of the null deletion.) and
GSTT1(A proportion of the population, varying from 12%–20% in
Europeans to 65% in Asians carries a null polymorphism (deletion).
Such people do not express the gene and therefore do not have any
GSST1 enzyme activity) were investigated in relation to breast
cancer risk. The study population consisted of 115 incident breast
cancer cases and 132 age-matched controls with no known malignant
diseases. GSTM1/T1 genotypes were determined by a multiplex
polymerase chain reaction (PCR) method, and odds ratios (ORs) and
95 % confidence intervals (CIs) were calculated by conditional
logistic regression model. The relative odds ratio (95 % confidence
interval) of breast cancer was 1.227 (0.68–2.22) with the GSTM1
null, 1.08 (0.64–1.81) with the GSTT1 null. The results
conclusively show that single gene GST polymorphisms do not confer
a substantial risk of breast cancer to its carriers.
This work was supported by grants AV4/0013/05,
MVTS Bil/ČR/S/UK/06, 2005/14MFN-06 (Slovak Ministry of Health) and
VEGA Fund 1/3379/06.
Datum přednesení příspěvku: 7. 12. 2006